Focused On-demand Library for Mediator of RNA polymerase II transcription subunit 29

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9NX70

UPID:

MED29_HUMAN

Alternative names:

Intersex-like protein; Mediator complex subunit 29

Alternative UPACC:

Q9NX70; B4DNQ6; M0R2E4; Q5XX09; Q9NTF4

Background:

Mediator of RNA polymerase II transcription subunit 29, also known as Intersex-like protein and Mediator complex subunit 29, plays a pivotal role in the transcription of RNA polymerase II-dependent genes. It acts as a coactivator, facilitating the transfer of information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. This protein is essential for the assembly of a functional preinitiation complex, incorporating RNA polymerase II and general transcription factors.

Therapeutic significance:

Understanding the role of Mediator of RNA polymerase II transcription subunit 29 could open doors to potential therapeutic strategies.